Left Atrial Appendage (LAA) Occluders

This channel includes news and new technology innovations about Left Atrial Appendage (LAA) Occluders. These close off the LAA in patients with atrial fibrillation to prevent the formation of stroke-causing clots in atrial fibrillation (AFib or AF) patients. LAA occlusion is often indicated for patients who do not tolerate anticoagulation therpy or have bleeding risks associated with use of that therapy.

The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.
Feature | ACC | April 09, 2020 | Dave Fornell, Editor
Here is the list of American College of Cardiology (ACC) practice-changing late-breaking study presentations at the ACC...
Videos | Structural Heart | February 27, 2020
Charles D. Resor, M.D., MSc, assistant director, cardiac catheterization lab, Tufts Medical Center and assistant...
The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess Abbott's Amplatzer Amulet left atrial appendage (LAA) occluder for people with atrial fibrillation (AF or AFib). 
News | Left Atrial Appendage (LAA) Occluders | February 03, 2020
February 3, 2020 — The U.S. Food and Drug Administration (FDA) has approved a the CATALYST trial designed to assess...
Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke risk in atrial fibrillation (AF) patients, announced that it has been selected from among hundreds of startups as a finalist for the ICI Innovation Award Competition. It uses a transcatheter lasso system so no implant is left behind and eliminates the possibility of embolization.

News | Left Atrial Appendage (LAA) Occluders | December 18, 2019
December 18, 2019 — Append Medical, developer of a novel left atrial appendage (LAA) closure device to minimize stroke...
AtriCure Receives Clearance for Expanded Labeling Claims for AtriClip Devices
News | Left Atrial Appendage (LAA) Occluders | August 28, 2019
August 28, 2019 — AtriCure Inc. announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of...
FEops HEARTguide Wins CSI Highlight of the Year Award
News | Structural Heart | July 05, 2019
July 5, 2019 — FEops announced that FEops HEARTguide was the winning entry at CSI Frankfurt 2019 voted on by physician...
Videos | Atrial Fibrillation | June 21, 2019
Sanjaya Gupta, M.D., electrophysiologist, St. Luke's Mid America Heart Institute, and assistant professor, University...
Boston Scientific Initiates OPTION Trial of Watchman FLX
News | Left Atrial Appendage (LAA) Occluders | June 12, 2019
June 12, 2019 — Boston Scientific Corp. has initiated the OPTION trial to compare safety and effectiveness of the next-...
Videos | Left Atrial Appendage (LAA) Occluders | April 25, 2019
This video offers an overview of the Watchman left atrial appendage (LAA) occluder system, including information of its...
Videos | Left Atrial Appendage (LAA) Occluders | October 01, 2018
Ashish Pershad, M.D., medical director, structural heart program, Banner University Medical Heart Institute, Phoenix,...
Watchman FLX in Clinical Trial at MedStar Heart and Vascular Institute
News | Left Atrial Appendage (LAA) Occluders | June 26, 2018
June 26, 2018 — MedStar Heart & Vascular Institute physicians participating in a clinical trial have become the...
A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman LAA Occluder device in an echo image. #HRS2018

A slide image from Reddy's presntation at Heart Rhythm 2018, showing thrombus formation on the face of a Watchman device in an echo image.

Feature | Left Atrial Appendage (LAA) Occluders | May 18, 2018
May 18, 2018 — Left atrial appendage closure (LAAC) with the transcatheter Watchman device prevents thromboembolism...
AtriCure Launches AtriClip FLEX•V Device in the United States
Technology | Left Atrial Appendage (LAA) Occluders | February 22, 2018
February 22, 2018 — AtriCure Inc. announced that it has launched the AtriClip FLEX•V Left Atrial Appendage (LAA)...
J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib
News | Left Atrial Appendage (LAA) Occluders | January 18, 2018
January 18, 2018 – Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc., a worldwide...
Videos | Medical 3-D Printing | November 17, 2017
Dee Dee Wang, M.D., director, structural heart imaging at Henry Ford Hospital, Detroit, explains how her center uses 3-...